Patent 10479975 was granted and assigned to Bluebird Bio on November, 2019 by the United States Patent and Trademark Office.
The invention provides improved T cell compositions and methods for manufacturing T cells. More particularly, the invention provides methods of T cell manufacturing that result in adoptive T cell immunotherapies with improved survival, expansion, and persistence in vivo.